Published by Global Banking & Finance Review®
Posted on March 5, 2026
1 min readLast updated: April 2, 2026
Add as preferred source on GoogleGalderma delivered record 2025 net sales of $5.21 billion (up 17.7% constant currency), led by a strong Therapeutic Dermatology segment powered by Nemluvio. It issued optimistic 2026 guidance—17–20% net sales growth and ~26% core EBITDA margin—boosting shares.
March 5 (Reuters) - Shares of Swiss skincare company Galderma opened higher on Thursday after it reported 17.7% growth in full-year net sales and gave an upbeat guidance for 2026.
The annual net sales were $5.21 billion, with the strongest growth coming from its Therapeutic Dermatology business, where sales grew more than 50% largely thanks to the recently launched Nemluvio product, which is used to treat chronic skin conditions atopic dermatitis and prurigo nodularis.
The company expects net sales growth of 17% to 20% and a core profit margin of about 26% on a constant-currency basis for 2026.
The shares gained around 7% by 0850 GMT, with Vontobel analysts saying the guidance was stronger than expected.
(Reporting by Marleen Kaesebier in Gdansk, editing by Milla Nissi-Prussak)
Galderma reported 17.7% growth in full-year net sales, totaling $5.21 billion.
The Therapeutic Dermatology segment experienced the strongest growth, with sales rising over 50%.
The newly launched Nemluvio product, used to treat atopic dermatitis and prurigo nodularis, fueled the segment's growth.
Galderma expects 17% to 20% net sales growth and a core profit margin of about 26% for 2026.
Galderma shares rose around 7% following the release of its strong sales results and 2026 guidance.
Explore more articles in the Finance category
